Research programme: phosphotransferase inhibitors - Ignyta

Drug Profile

Research programme: phosphotransferase inhibitors - Ignyta

Alternative Names: RXDX-102; RXDX-103; RXDX-104

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta
  • Class
  • Mechanism of Action CDC7 protein kinase inhibitors; Proto oncogene protein c ret inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Mar 2016 Ignyta has patent protection for RXDX 103 in USA (Ignyta 10-K, March 2016)
  • 26 Feb 2016 Ignyta discontinues development RXDX 103 in USA for Cancer (Ignyta 10-K, March 2016)
  • 15 Dec 2014 Nerviano and Ignyta amend licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top